Invasive meningococcal disease in Italy: from analysis of national data to an evidence-based vaccination strategy.
Anti-meningococcal vaccination strategies
Epidemiology
Invasive meningococcal diseases
Surveillance system
Journal
Journal of preventive medicine and hygiene
ISSN: 2421-4248
Titre abrégé: J Prev Med Hyg
Pays: Italy
ID NLM: 9214440
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
05
2020
accepted:
23
06
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
10
7
2021
Statut:
epublish
Résumé
Invasive meningococcal disease (IMD) is one of the most severe vaccine-preventable disease not yet under control. In Italy, although different anti-meningococcal vaccines are available, their offer among regions is heterogeneous. The aim of this study is to describe the epidemiology of IMD in Italy based on analysis of national surveillance data for 2011-2017 to optimize the vaccination strategy. IMD surveillance data from the Italian National Health Institute were analysed. Microsoft Excel was used to present trend analysis, stratifying by age and serogroups. In Italy, during the period 2011-2017, the incidence of IMD increased from 0.25 cases/100,000 inhabitants in 2011 to 0.33 cases/100,000 in 2017. Most cases after 2012 were caused by non-B serogroups. The number of cases in subjects aged 25-64 years increased steadily after 2012 (36 cases in 2011, 79 in 2017), mostly due to non-B serogroups, representing more than 65% of cases in those aged 25+ years. In the period from 2011 to 2017, the incidence of IMDs increased in Italy. The increase, probably due also to a better surveillance, highlights the importance of the disease in the adult population and the high level of circulation of non-B serogroups in particular after 2012. Our analysis supports an anti-meningococcal vaccination plan in Italy that should include the highest number of preventable serogroups and be aimed at vaccinating a wider population through a multicohort strategy.
Identifiants
pubmed: 32802999
doi: 10.15167/2421-4248/jpmh2020.61.2.1589
pmc: PMC7419122
doi:
Substances chimiques
Meningococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E152-E161Informations de copyright
©2020 Pacini Editore SRL, Pisa, Italy.
Déclaration de conflit d'intérêts
Conflicts of interest statement SI, LB, SP and GCL work for Sanofi Pasteur Italia. The other authors declare no conflict of interest.
Références
Int J Environ Res Public Health. 2018 May 17;15(5):
pubmed: 29772848
J Infect. 2016 Aug;73(2):136-44
pubmed: 27235364
Euro Surveill. 2016 Nov 10;21(45):
pubmed: 27918265
PLoS One. 2019 Mar 13;14(3):e0212922
pubmed: 30865671
Indian J Med Microbiol. 2006 Jan;24(1):7-19
pubmed: 16505549
Clin Microbiol Infect. 2019 Jan;25(1):111.e1-111.e4
pubmed: 30036673
BMJ Open. 2019 Apr 20;9(4):e024343
pubmed: 31005910
PLoS One. 2015 Oct 07;10(10):e0139376
pubmed: 26445461
BMC Infect Dis. 2009 Feb 05;9:13
pubmed: 19196453
Vaccine. 2019 Jan 3;37(1):41-48
pubmed: 30478004
Vaccine. 2018 Sep 25;36(40):5962-5966
pubmed: 30172636
Vaccine. 2017 Apr 11;35(16):2034-2041
pubmed: 28314560
Euro Surveill. 2018 Apr;23(16):
pubmed: 29692317
Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
pubmed: 19477562
Crit Care. 2010;14(3):R124
pubmed: 20587048
Clin Infect Dis. 2015 Apr 15;60(8):e27-35
pubmed: 25605282
Vaccine. 2012 May 30;30 Suppl 2:B26-36
pubmed: 22178525
BMJ Open. 2017 May 2;7(4):e012478
pubmed: 28465304
Pediatrics. 2009 Mar;123(3):e502-9
pubmed: 19254985
J Clin Microbiol. 2003 Dec;41(12):5783-6
pubmed: 14662983
Vaccine. 2014 Aug 20;32(37):4791-8
pubmed: 24998605
Vaccine. 2018 Jul 5;36(29):4222-4227
pubmed: 29895504
Int J Environ Res Public Health. 2018 Jul 18;15(7):
pubmed: 30021934
Crit Rev Microbiol. 2016 Sep;42(5):759-72
pubmed: 26089023
Expert Rev Vaccines. 2011 Oct;10(10):1477-86
pubmed: 21988310
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):271-6
pubmed: 8990198
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
Emerg Infect Dis. 2016 Mar;22(3):469-75
pubmed: 26890305
Hum Vaccin Immunother. 2018 May 4;14(5):1203-1215
pubmed: 29543535
BMC Infect Dis. 2019 Jan 8;19(1):29
pubmed: 30621624
Infect Dis Ther. 2018 Dec;7(4):421-438
pubmed: 30267220
Clin Infect Dis. 2015 Feb 15;60(4):578-85
pubmed: 25389259
Vaccine. 2016 Mar 18;34(13):1515-1523
pubmed: 26876439
J Infect Dis. 2010 Apr 15;201(8):1208-24
pubmed: 20199241
Expert Rev Anti Infect Ther. 2011 Sep;9(9):761-74
pubmed: 21905785
J Clin Microbiol. 2014 Jun;52(6):1901-10
pubmed: 24648565
Expert Rev Vaccines. 2019 Jan;18(1):15-30
pubmed: 30526162
Infect Dis Ther. 2019 Sep;8(3):307-333
pubmed: 31347097
J Infect. 2013 Nov;67(5):385-90
pubmed: 23796865
Int J Infect Dis. 2019 Aug;85:37-48
pubmed: 31085314